NDA for Atopic Dermatitis Indication of the Class 1 innovative drug Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
2025-10-30

NDA for Atopic Dermatitis Indication of the Class 1 innovative drug Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China

Awarded for Five Consecutive Years! CMS’s Subsidiary Shenzhen Kangzhe Once Again Listed in “Shenzhen Top 500 Enterprises”
2025-10-28

Awarded for Five Consecutive Years! CMS’s Subsidiary Shenzhen Kangzhe Once Again Listed in “Shenzhen Top 500 Enterprises”

CMS Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®
2025-10-27

CMS Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®

Honored with 2025 Listed Company “Shareholder Return Crystal Ball Award” and “ESG Crystal Ball Award” by Weekly on Stocks
2025-10-17

Honored with 2025 Listed Company “Shareholder Return Crystal Ball Award” and “ESG Crystal Ball Award” by Weekly on Stocks

Approval of Drug Clinical Trials for Additional Chronic Obstructive Pulmonary Disease Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection
2025-09-30

Approval of Drug Clinical Trials for Additional Chronic Obstructive Pulmonary Disease Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection

Approval of Phase III Drug Clinical Trials for Additional Chronic Spontaneous Urticaria Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection
2025-09-28

Approval of Phase III Drug Clinical Trials for Additional Chronic Spontaneous Urticaria Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection

Awarded the “Best Listed Company” prize at the 2025 “Golden Kunpeng” China Financial Value Ranking Event

Awarded the “Best Listed Company” prize at the 2025 “Golden Kunpeng” China Financial Value Ranking Event

Listed in the “Industry-Leading Pharmaceutical Enterprises”

Listed in the “Industry-Leading Pharmaceutical Enterprises”

Self-developed Innovative Drug GnRH Receptor Antagonist CMS-D002 is Approved for Uterine Fibroids Indication
2025-09-26

Self-developed Innovative Drug GnRH Receptor Antagonist CMS-D002 is Approved for Uterine Fibroids Indication

Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication

Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication

Signed Collaboration Agreements for Class 1 Innovative Biologics Vecantoxatug Injection (Passive Immunization Against Tetanus) and Silevimig Injection (Passive Immunization Against Rabies)
2025-09-22

Signed Collaboration Agreements for Class 1 Innovative Biologics Vecantoxatug Injection (Passive Immunization Against Tetanus) and Silevimig Injection (Passive Immunization Against Rabies)

Awarded “2025 ESG Exemplary Enterprise Award” at the International Green Zero-Carbon Festival
2025-09-08

Awarded “2025 ESG Exemplary Enterprise Award” at the International Green Zero-Carbon Festival